BACE1 and Alzheimer disease: A positron emission tomography (PET) imaging agent for the quantification of BACE1 activity in the brain can be an important tool to complement the existing portfolio of radiopharmaceuticals used for evaluation of patients with cognitive impairment in neurodegenerative diseases such as AD.